For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- KM Biologics’s Smallpox Vaccine in Line to Add Monkeypox Use
August 1, 2022
- New Expert Panel to Issue Proposals for 2023, 2024 Price Revisions; Official Spearheading Debate Prods Industry to Speak Up
July 29, 2022
- Online Submissions for Partial Changes of Generics to Start from October
July 29, 2022
- MHLW Panel OKs 60 More Health Damage Claims for COVID-19 Vaccines
July 29, 2022
- Japan Detects 2nd Monkeypox Case in Tokyo
July 29, 2022
- Supply Chain Clause of Economic Security Law to Be Enforced on Aug. 1
July 28, 2022
- MHLW Eyes Omicron-Specific Jabs for All Residents Given Primary Inoculations
July 26, 2022
- Panel OKs COVID-Flu Shots to Be Given Simultaneously
July 26, 2022
- Japan Panel Recognizes 1st Death Linked to COVID Vaccination
July 26, 2022
- 8 New Probable Cases of Pediatric Hepatitis Reported in Japan
July 26, 2022
- Japan Confirms 1st Monkeypox Case
July 26, 2022
- 4th COVID Jabs Approved for Healthcare Providers: MHLW
July 25, 2022
- Omicron-Specific Boosters to Be Introduced This Fall or Later: Panel
July 25, 2022
- KM Biologics’s Smallpox Vaccine Up for Review for Monkeypox Use
July 25, 2022
- Japan to Boost Measures to Ensure COVID Drug Access, Govt Says after Shionogi Antiviral Delay
July 22, 2022
- Label Expansions for Onoact, Ultomiris Up for MHLW Panel Review on Aug. 4
July 22, 2022
- Komeito Lawmakers Call for Assessing Shionogi’s Pill for Circulating Strains
July 22, 2022
- Japan Plans Smaller Drug Price Survey for 2023 Revision, Just Like 2 Years Ago
July 21, 2022
- Imfinzi, Bavencio to Add Encephalitis Risks in Label Revision
July 21, 2022
- Janssen’s CAR-T Therapy, Kymriah Label Expansion Up for Review on Aug. 3
July 21, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…